ISSN 2348-0319 International Journal of Innovative and Applied Research [2023]
(Volume 11, Issue 12)
35-40

Journal home page: http://www.journalijiar.com

INTERNATIONAL JOURNAL
OF INNOVATIVE AND APPLIED RESEARCH

RESEARCH ARTICLE

Article DOI: 10.58538/IJIAR/2059
DOI URL: *http://dx.doi.org/10.58538/IJIAR/2059*

EXPLORING PREDISPOSITION: RISK FACTORS AND SICKLE CELL ANEMIA ONSET

Emmanuel Ifeanyi Obeagu[1], Emmanuel Chinedu Onuoha[2] and Getrude Uzoma Obeagu[3]

1. Department of Medical Laboratory Science, Kampala International University, Uganda.
2. Department of Haematology and Blood Transfusion, Faculty of Medical and Laboratory Science, Federal University Otuoke, Bayelsa State, Nigeria.
3. School of Nursing Science, Kampala International University, Uganda.

Manuscript Info

Manuscript History
Received: 25 October 2023
Final Accepted: 02 December 2023
Published: December 2023

Keywords:
Sickle Cell Anemia, Risk Factors, Genetic Predisposition, Environmental Influences, Early Detection, Disease Management

Abstract

Sickle cell anemia (SCA) stands as a prominent hereditary hemoglobinopathy characterized by a mutated form of hemoglobin, culminating in diverse clinical complications. These paper endeavors to synthesize the multifaceted aspects contributing to SCA's onset and progression, delineating the intricate interplay of genetic, environmental, and lifestyle factors in shaping the disease's phenotype and severity. Genetically, variations in the HBB gene encoding beta-globin hold paramount importance in SCA, elucidating diverse mutation patterns and their correlation with disease severity. Furthermore, the influence of gene modifiers and their contribution to the wide spectrum of phenotypic diversity among individuals carrying the sickle cell trait is expounded upon. Beyond genetic predisposition, environmental elements wield significant influence. Geographical factors, climatic conditions, infectious agents, and socio-economic determinants are examined for their impact on disease prevalence and progression. The review extends its scope to encompass lifestyle factors, illuminating the roles of nutrition, physical activity, and psychosocial stress in shaping the clinical course of SCA.A pivotal facet in mitigating the burden of SCA lies in early detection and intervention. Exploring current screening methodologies, prognostic indicators, and emerging technologies for timely diagnosis and tailored therapeutic strategies offers promise in ameliorating complications and enhancing patient outcomes.

***Corresponding Author:-** **Emmanuel Ifeanyi Obeagu,** *Department of Medical Laboratory Science, Kampala International University, Uganda.*

Introduction:-

Sickle cell anemia (SCA) stands as a paradigmatic exemplar of the intricate interplay between genetic predisposition, environmental influences, and the resultant clinical manifestations of a hereditary disorder [1-5]. First described over a century ago, this hemoglobinopathy continues to pose significant challenges in understanding its heterogeneous presentation and devising effective management strategies. The affliction arises from a single point mutation in the HBB gene, encoding the beta-globin chain of hemoglobin, yet its clinical expression manifests with remarkable variability among individuals, prompting a deeper investigation into the multifaceted influences

predisposing individuals to this complex disorder [6-11].Genetic factors remain the cornerstone in elucidating the underpinnings of sickle cell anemia. A spectrum of mutations within the HBB gene coupled with the influence of modifying genes intricately shapes the phenotypic diversity observed in affected individuals. The varying clinical trajectories, ranging from asymptomatic carriers to severe morbidity, underscore the pivotal role of genetic determinants while beckoning a nuanced comprehension of additional influences contributing to disease onset and progression [12-16].

However, the narrative of sickle cell anemia extends far beyond the confines of genetic predisposition. Environmental factors, such as geographical location, climatic conditions, prevalence of infectious diseases, and socio-economic determinants, have emerged as pivotal influencers shaping the phenotypic expression and severity of the disorder. Moreover, the recognition of lifestyle elements—nutrition, physical activity, and psychosocial stress—as contributors further complicates the comprehensive understanding of this multifaceted condition.Despite advances in diagnostics and treatment modalities, the landscape of sickle cell anemia management remains intricate and challenging. Early detection holds promise in altering disease trajectories, allowing for timely interventions and personalized therapeutic strategies. This necessitates a profound exploration into existing screening methodologies, prognostic indicators, and emerging technologies that empower clinicians to intervene at critical junctures, thereby mitigating the burden of complications and improving patient outcomes [17-21].This paper endeavors to synthesize the complex tapestry of genetic, environmental, and lifestyle factors influencing the onset and progression of sickle cell anemia. By illuminating these intricate elements, we aspire to pave the way for a more comprehensive understanding of the disorder, fostering tailored interventions and ultimately alleviating the burden experienced by individuals and healthcare systems alike.

Genetic Predisposition

Genetic factors constitute the foundational framework underlying the etiology and manifestation of sickle cell anemia (SCA). The hallmark of this hereditary disorder lies in a point mutation within the HBB gene, leading to the substitution of a single amino acid in the beta-globin chain of hemoglobin. This seemingly minor alteration from glutamic acid to valine precipitates the formation of hemoglobin S (HbS), inducing the distinctive sickling of red blood cells under conditions of low oxygen tension [22-27].The wide spectrum of clinical presentations observed in SCA individuals can be attributed to the heterogeneous nature of genetic influences. Beyond the primary mutation responsible for HbS, the presence of other genetic modifiers plays a pivotal role in modulating disease severity. Factors such as fetal hemoglobin (HbF) levels, the presence of alpha-globin gene variants, and coinheritance of specific genetic polymorphisms significantly influence the phenotypic diversity seen among individuals carrying the sickle cell trait [28-32].Furthermore, the inheritance pattern of sickle cell anemia, predominantly autosomal recessive, contributes to the complexities in disease expression. Carriers of a single copy of the mutated HBB gene, commonly referred to as sickle cell trait carriers, may exhibit asymptomatic or mild manifestations. However, the coinheritance of two mutated copies leads to the clinical spectrum of sickle cell disease, characterized by recurrent vaso-occlusive crises, chronic organ damage, and increased susceptibility to infections [33-36].Genetic counseling and screening programs have become indispensable tools in identifying carriers and elucidating the risk of transmission to offspring, thereby empowering individuals and families to make informed decisions regarding family planning and reproductive choices. Emerging therapies targeting the genetic basis of SCA, such as gene editing and gene therapy, hold promise in offering potential curative avenues by correcting the underlying genetic defects [37-39].While genetic factors lay the foundation for sickle cell anemia, their interaction with environmental and lifestyle determinants further shapes the clinical trajectory of the disease. Hence, comprehending the intricate interplay between genetic predisposition and other influencing factors remains pivotal in devising holistic approaches to manage and mitigate the impact of SCA.

Environmental and Lifestyle Influences

Beyond the genetic underpinnings, sickle cell anemia (SCA) is influenced by a spectrum of environmental and lifestyle factors that intricately shape its clinical course and overall impact on affected individuals.

Environmental Factors

Geographical variations significantly influence the prevalence and severity of sickle cell anemia. Regions with a high prevalence of malaria historically demonstrated a survival advantage for individuals carrying the sickle cell trait due to the protective effect against severe malaria conferred by heterozygosity. Conversely, in areas with limited access to healthcare resources, inadequate management of complications exacerbates the burden of SCA, leading to higher morbidity and mortality rates [40].Climatic conditions also play a role, as extreme temperatures

and dehydration can precipitate vaso-occlusive crises, one of the hallmark manifestations of SCA. Additionally, exposure to high altitudes with lower oxygen tension can exacerbate symptoms, underscoring the environmental sensitivity of the disease.The prevalence and impact of infectious diseases, such as bacterial infections or viral illnesses, further complicate the clinical course of SCA. Individuals with sickle cell disease are more susceptible to certain infections due to functional asplenia and compromised immune responses, emphasizing the need for vigilant preventive measures and prompt treatment [41].

Lifestyle Factors

Nutrition plays a crucial role in managing sickle cell anemia [42]. Adequate hydration and a balanced diet rich in nutrients, especially folic acid, aid in minimizing complications and supporting overall health. However, dietary deficiencies and poor nutrition can exacerbate symptoms and increase the frequency of crises.Regular physical activity, tailored to individual capabilities, contributes to improved cardiovascular health and overall well-being in individuals with SCA. Conversely, excessive physical exertion or inadequate rest may trigger crises, necessitating a delicate balance in maintaining an active yet cautious lifestyle [43].Psychosocial factors, including stress and mental health, significantly impact the disease course. Stressful events or emotional distress can precipitate crises or worsen existing symptoms, highlighting the need for holistic care that addresses the psychological well-being of individuals living with SCA.Understanding the interplay between environmental factors, lifestyle choices, and sickle cell anemia is crucial for devising comprehensive management strategies. Educational interventions aimed at promoting awareness, facilitating access to healthcare, and advocating for supportive environments can significantly improve outcomes and enhance the quality of life for individuals affected by SCA. Incorporating these considerations into holistic care plans fosters a more nuanced approach to managing this complex hemoglobinopathy.

Early Detection and Intervention

Timely identification and intervention are paramount in mitigating the impact of sickle cell anemia (SCA), aiming to alleviate complications, enhance quality of life, and improve overall outcomes for affected individuals. Early detection strategies, coupled with tailored interventions, constitute crucial components in the management of this complex hemoglobinopathy [44].

Screening and Diagnosis

Early detection begins with comprehensive screening programs aimed at identifying infants, newborns, and individuals at risk for sickle cell disease. Neonatal screening, typically performed through hemoglobin electrophoresis or high-performance liquid chromatography, facilitates the identification of affected newborns, enabling prompt initiation of interventions and supportive care [44].Advancements in molecular diagnostics, such as DNA-based testing for hemoglobinopathies, offer greater precision in identifying carriers and individuals with sickle cell traits, enhancing the accuracy and accessibility of screening methodologies.

Prognostic Indicators and Monitoring

Establishing prognostic indicators aids in predicting disease severity and potential complications. Biomarkers, such as levels of fetal hemoglobin (HbF), hemolytic markers, and inflammatory mediators, serve as valuable tools in assessing disease progression and guiding treatment strategies [45].Regular monitoring of clinical parameters, including hematological indices, organ function, and disease-specific complications, forms the cornerstone of disease management, allowing for timely intervention and adjustment of therapeutic modalities based on individualized needs.

Early Intervention and Disease Management

Initiating early interventions upon diagnosis is pivotal in preventing and managing complications associated with SCA [46]. Prophylactic measures, including vaccinations, antibiotic prophylaxis for infections, and hydroxyurea therapy, have demonstrated efficacy in reducing the frequency and severity of vaso-occlusive crises and associated complications.Comprehensive care plans, encompassing pain management strategies, blood transfusions when indicated, and adherence to a regimen of folic acid supplementation, are essential components of managing SCA. Additionally, specialized clinics and multidisciplinary care teams play a crucial role in providing holistic care tailored to the diverse needs of individuals living with SCA.

Emerging Therapeutic Avenues

Advancements in medical research have led to promising therapeutic approaches, including gene therapy and gene editing techniques, aimed at addressing the underlying genetic defect responsible for sickle cell disease. These

innovative interventions hold potential for offering curative options, heralding optimism for improved long-term outcomes in affected individuals [47]. Early detection facilitated by robust screening programs, coupled with vigilant monitoring and timely intervention strategies, forms the cornerstone of effective management in sickle cell anemia. Embracing a comprehensive and multidisciplinary approach to care, encompassing both conventional therapies and emerging modalities, holds promise in enhancing the quality of life and prognosis for individuals grappling with this multifaceted hematological disorder.

Conclusion:-

Sickle cell anemia (SCA) epitomizes the intricate interplay between genetic predisposition, environmental influences, and multifaceted clinical manifestations. The culmination of genetic mutations within the HBB gene encoding beta-globin, coupled with various modifying factors, lays the groundwork for the heterogeneous spectrum of disease severity and phenotype observed among affected individuals.While genetic factors remain foundational, environmental determinants intricately shape the clinical trajectory of SCA. Geographical variations, climatic conditions, prevalence of infectious diseases, and socio-economic factors significantly impact disease prevalence, complications, and access to healthcare, underscoring the multifaceted nature of this hemoglobinopathy.Moreover, lifestyle choices, encompassing nutrition, physical activity, and psychosocial well-being, play pivotal roles in modulating disease outcomes. Balancing these factors is crucial to minimize the frequency of vaso-occlusive crises, manage complications, and enhance overall quality of life for individuals living with SCA.Early detection strategies, facilitated by comprehensive screening methodologies and advanced diagnostic tools, are pivotal in initiating timely interventions and tailoring therapeutic approaches. Prognostic indicators aid in monitoring disease progression, guiding treatment decisions, and optimizing care plans to meet individualized needs.Continued advancements in therapeutic modalities, such as gene editing and gene therapy, offer promising avenues towards potential cures, fostering hope for improved long-term outcomes and quality of life for individuals affected by SCA.

A holistic and multidisciplinary approach that integrates genetic insights with environmental considerations, lifestyle modifications, early detection, and emerging therapeutic strategies is paramount in mitigating the impact of SCA. Empowering individuals, advocating for equitable access to healthcare, and fostering research collaborations are pivotal in the ongoing pursuit of comprehensive management strategies and, ultimately, the alleviation of the burden imposed by this complex hematological disorder. Through concerted efforts, we endeavor to pave the way towards improved care, enhanced outcomes, and a brighter future for those navigating the challenges of sickle cell anemia.

References:-

1. Pecker LH, Little J. Clinical manifestations of sickle cell disease across the lifespan. Sickle cell disease and hematopoietic stem cell transplantation. 2018:3-9.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):2244-52.
3. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-1.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
6. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-7.
7. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
8. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
9. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
10. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP. Men's Essential roles in the Management of Sickle Cell Anemia. Newport International Journal of Scientific and Experimental Sciences 4(2):20-29.https://doi.org/10.59298/NIJSES/2023/10.3.1111
11. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41

12. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research. 2023; 6(1):2768-0487.
13. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-9.
14. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023 Dec 1;102(48): e36462.
15. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students of The University of Calabar. Prevalence.;5(100):0-5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
17. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023; 1:1-7.
18. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-5.
19. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-3.
20. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-8.
21. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-34.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-5.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants in the Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018; 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
25. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
26. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2023;3(1):1-6.
27. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-7.
28. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
29. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-4.
30. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-3.
31. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-5.
32. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-5.
33. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-43.
34. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-3.
35. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. Paripex - Indian Journal of Research, 2015; 4(6): 258-259

36. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-5.
37. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
38. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michaelokpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-50.
39. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
40. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. Environmental determinants of severity in sickle cell disease. Haematologica. 2015;100(9):1108.
41. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, Savio J, Sethuraman N, Madan S, Shastri P, Thangaraju D. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerging infectious diseases. 2021;27(9):2349.
42. Khan SA, Damanhouri G, Ali A, Khan SA, Khan A, Bakillah A, Marouf S, Al Harbi G, Halawani SH, Makki A. Precipitating factors and targeted therapies in combating the perils of sickle cell disease---A special nutritional consideration. Nutrition & metabolism. 2016;13(1):1-2.
43. Roychowdhury D. Mindfulness practice during COVID-19 crisis: Implications for confinement, physical inactivity, and sedentarism. Asian Journal of Sport and Exercise Psychology. 2021;1(2-3):108-15.
44. Anurogo D, Yuli Prasetyo Budi N, Thi Ngo MH, Huang YH, Pawitan JA. Cell and gene therapy for anemia: Hematopoietic stem cells and gene editing. International journal of molecular sciences. 2021;22(12):6275.
45. Bellos I, Pergialiotis V, Loutradis D, Papapanagiotou A, Daskalakis G. The role of hemoglobin degradation pathway in preeclampsia: A systematic review and meta-analysis. Placenta. 2020; 92:9-16.
46. Geethakumari K, Kusuma YS, Babu BV. Beyond the screening: the need for health systems intervention for prevention and management of sickle cell disease among tribal population of India. The International Journal of Health Planning and Management. 2021;36(2):236-43.
47. Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Frontiers in physiology. 2020; 11:435.